BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shandong New Time Pharmaceutical Co.\, Ltd. readouts · AssetM
 emo
X-WR-CALDESC:Upcoming readouts of studies Shandong New Time Pharmaceutical 
 Co.\, Ltd.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07312188-3212@assetmemo.bio
DTSTAMP:20261121T011044Z
DTSTART;VALUE=DATE:20280520
DTEND;VALUE=DATE:20280521
SUMMARY:F182112: Phase 2 readout est. (NCT07312188)
DESCRIPTION:F182112\, phase 2\, Multiple Myeloma.\nStudy: A Study of F18211
 2 in the Treatment of Patients With Relapsed or Refractory Multiple Myelom
 a\nEstimated primary completion: 20 May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/f182112#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07312188
URL:https://assetmemo.bio/drug/f182112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579234-3212@assetmemo.bio
DTSTAMP:20261121T011044Z
DTSTART;VALUE=DATE:20290125
DTEND;VALUE=DATE:20290126
SUMMARY:F182112: Phase 3 readout est. (NCT07579234)
DESCRIPTION:F182112\, phase 3\, Multiple Myeloma.\nStudy: A Multicenter\, R
 andomized\, Open-label\, Parallel-group\, Controlled\, Superiority Phase I
 II Clinical Study Comparing the Efficacy and Safety of F182112 Versus Stan
 dard of Care in Patients With Relapsed or Refractory Multiple Myeloma\nEst
 imated primary completion: 25 January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/f182112#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07579234
URL:https://assetmemo.bio/drug/f182112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
